Press releases
Browse GSK global press releases issued since 2009. Search them by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
-
GSK submits regulatory application in Japan for once-daily single inhaler triple therapy FF/UMEC/VI for patients with COPD
GlaxoSmithKline plc and Innoviva, Inc. today announced the submission of a regulatory application to the Japanese Ministry of Health,
-
ViiV Healthcare receives EU marketing authorisation for Juluca (dolutegravir/rilpivirine), the first 2-drug regimen, once-daily, single-pill for the treatment of HIV
Juluca maintains viral suppression with two drugs in the smallest single pill regimen
-
GSK receives US approval of Arnuity Ellipta for use in children from 5 years old who suffer from asthma
GSK today announced it has received approval from the US Food and Drug Administration (FDA) for the use of Arnuity Ellipta
-
Nucala (mepolizumab) study reports long-term safety data, consistent exacerbation reduction and improved asthma control
New study showed one third of patients had no exacerbations on long-term treatment with Nucala.
-
GSK’s industry-leading respiratory research and scientific innovation showcased at ATS conference
GlaxoSmithKline plc (GSK) will present at the American Thoracic Society (ATS) conference in San Diego, USA, 19-23 May 2018.
-
Simon Dingemans, Chief Financial Officer, to retire from GSK
Simon Dingemans, Chief Financial Officer, GSK, has informed the Board of his intention to retire from the Company in May 2019.
-
GSK delivers Q1 sales of £7.2 billion, -2% AER, +4% CER
Total EPS 11.2p, -48% AER, -33% CER; Adjusted EPS 24.6p, -2% AER, +11% CER
-
Once-daily Trelegy Ellipta gains expanded indication in the US for the treatment of patients with COPD
Expanded indication approved for Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol ‘FF/UMEC/VI’)
-
Landmark IMPACT study published in NEJM shows significant benefits of Trelegy Ellipta for patients with COPD
Once-daily single inhaler triple therapy superior to Relvar/Breo Ellipta and Anoro Ellipta across multiple endpoints
-
GSK appoints Kevin Sin as new SVP and Head of Worldwide Business Development for R&D
Kevin Sin appointed as Senior Vice President and Head of Worldwide Business Development for Pharmaceuticals Research & Development.
-
GSK signs strategic agreement to transfer rare disease gene therapy portfolio to Orchard Therapeutics
Agreement strengthens Orchard’s position as a global leader in gene therapy for rare diseases.
-
GSK reaches agreement with Novartis to acquire full ownership of Consumer Healthcare Business
GSK reaches agreement with Novartis to acquire full ownership of Consumer Healthcare Business
-
ViiV Healthcare gains CHMP positive opinion for Juluca (dolutegravir/rilpivirine) in Europe
ViiV Healthcare announced that the European Committee for Medicinal Products for Human Use issued a Positive Opinion for Juluca.
-
Shingrix approved in Europe and Japan for the prevention of shingles in adults aged 50 and over
GSK announced the EC has approved Shingrix for the prevention of shingles & PHN in adults aged 50 years or older.
-
GSK update regarding Pfizer Inc. Consumer Healthcare
GlaxoSmithKline plc (LSE/NYSE: GSK) today confirms it has withdrawn from the process relating to Pfizer’s Consumer Healthcare business.
-
GSK starts phase III study of Benlysta and rituximab combination in systemic lupus erythematosus
GSK today announced the start of a phase III study investigating Benlysta (belimumab)
-
GSK announces positive EU approval for labelling update to Relvar Ellipta in patients with asthma
GSK & INVA announced that the EC has approved a label update for the use of once daily Relvar Ellipta (fluticasone furoate/vilanterol,FF/VI)
-
New clinical data demonstrate high vaccine efficacy of Fluarix Tetra (Influenza Vaccine) in children 6-35 months of age
New data published in The Lancet from a Phase III clinical trial with Fluarix Tetra which prevented influenza in children 6 to 35 months
-
ViiV Healthcare announces positive new dolutegravir data for the treatment of people living with HIV co-infected with tuberculosis
INSPIRING study results contribute to extensive body of evidence for dolutegravir
-
Nucala (mepolizumab) improved asthma control in patients uncontrolled on Xolair (omalizumab)
Positive clinical study outcomes observed for severe eosinophilic asthma patients uncontrolled on omalizumab